MVManjunatha Muniswamappa Venkataswamy

Manjunatha Muniswamappa Venkataswamy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Manjunatha Muniswamappa Venkataswamy has a total of 71 co-authors. Here are the top co-authors by number of shared publications:

  • Narendra Kumar

    Department of Pharmacology & Experimental Neuroscience, Durham Research Center, Nebraska Medical Center, 8052, 985800, Omaha, NE, 68198-5800, USA

    6 shared publications
  • Rashmi Santhoshkumar

    Electron Microscopy- Common Research Facility, Department of Neuropathology, NIMHANS, Bengaluru, India

    3 shared publications
  • Vasanthapuram Ravi

    Department of Neurovirology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India

    3 shared publications
  • Anita Desai

    Department of Neurovirology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India

    2 shared publications
  • Anita S. Desai

    Department of Neurovirology, National Institute of Mental Health and Neurosciences

    2 shared publications
  • B. G. Prakash Kumar

    State Surveillance Unit, Directorate of Health and Family Welfare, Government of Karnataka

    2 shared publications

Latest Publications

  • Open Access

    Ayurvedic Therapeutic Regimen as an Add-On to Optimized Conventional Management of Parkinson Disease: Protocol for an Exploratory Randomized Controlled Trial Evaluating Clinical, Cortical Excitability, Neuroimmune, and Autonomic Function Parameters

    by Umesh Chikkanna, Pramod Kumar Pal, Sophia Jameela, Rohan R Mahale, Nitish Kamble, Venkataram Shivakumar, Bharath Holla, Ravi Yadav, Vikram V Holla, Talakad Narasappa Sathyaprabha, et al.

    Background: Parkinson disease (PD), a progressive neurodegenerative disorder, lacks disease-modifying treatments. Current therapies focus on symptomatic relief, highlighting the need for adjunctive neuroprotective strategies. Ayurveda, a holistic system, shows promise in improving PD clinical outcomes. Objective: This assessor-blinded randomized controlled study aims to systematically evaluate the efficacy of an add-on Ayurveda therapeutic regimen compared to conventional treatment as usual (TAU) in improving the clinical outcomes of PD. Methods: A total of 80 patients with PD, diagnosed according to UK Parkinson’s Disease Society Brain Bank criteria, will be randomized into two groups: TAU and add-on Ayurveda. The intervention group will receive Ayurvedic therapy alongside conventional treatment for 180 days, whereas the control group will continue TAU. Assessments will occur at baseline and at 60-, 120-, and 180-day follow-ups, evaluating motor and nonmotor symptoms. Transcranial magnetic stimulation, heart rate variability, and pulmonary function tests will assess cortical excitability, autonomic function, and pulmonary function, respectively. Immunological parameters, including cytokine levels and telomere length, will be analyzed at baseline and at 180 days to explore disease-modifying effects. Liver and renal function tests will monitor safety. Results: As of 2025, a total of 259 patients with PD have been screened for eligibility, of whom 58 participants have been successfully enrolled in the trial. Among these, 33 participants have completed the intervention and follow-up assessments, 14 have discontinued participation, and 11 are currently continuing participation in the study. Recruitment and follow-up are ongoing, and the trial is scheduled for completion in September 2026. Conclusions: This study aims to address the lack of mechanistic evidence and robust data on Ayurveda in PD. By systematically evaluating clinical efficacy and potential biomechanisms, the findings will provide preliminary evidence for Ayurvedic interventions, potentially paving the way for their integration into comprehensive PD management.

  • Open Access

    Higher proportions of circulating CXCR3+ CCR6− Tfh cells as a hallmark of impaired CD4+ T-cell recovery in HIV-1-infected immunological non-responders

    by Ruthu Nagaraju, Pruthvi S. Gowda, Durai M. Gunasekaran, Anita S. Desai, Udaykumar Ranga, Ramesh N. R. Masthi, Manjunatha M. Venkataswamy

    Despite long-term suppressive antiretroviral therapy (ART), immune dysregulation due to impaired reconstitution of CD4+ T cells is a major hurdle for reducing morbidity and mortality in HIV-1-infected immunological non-responders (INRs, CD4+ T cells ≤350 cells/µL). To evaluate potential immunological factors associated with impaired CD4+ T-cell reconstitution, we performed comprehensive immunophenotyping of multiple subsets of CD4+ T cells among HIV-1-infected individuals with high (>350 cells/µL) and low (≤350 cells/µL) CD4+ T cells, either ART-naïve or ART-exposed (median, 10 years). In comparison to other groups, INRs showed exclusively elevated proportions of CXCR3+ CCR6− Th1-like circulatory T follicular helper (cTfh1) CD4+ T cells, correlating negatively with CD4+ T cells ( r = −0.6769, P < 0.0001), suggesting a strong association with incomplete CD4+ T-cell recovery. In contrast, compared to INRs, higher proportions of CXCR3− CCR6+ Th17-like cTfh cells (cTfh17) in immunological responders (IRs, CD4+ T cells >350 cells/µL) showed no correlation with CD4+ T-cell counts, suggesting a lack of association with CD4+ T-cell recovery. Additionally, proportions of activated (CD4+ CD38+ HLA-DR+) and regulatory (CD4+ CD25+/hi CD127−/lo) CD4+ T cells were increased in INRs compared to IRs, as previously known. A negative correlation was also observed between the CD4+ T-cell counts and activated ( r = −0.6726, P < 0.0001) or regulatory ( r = −0.5627, P < 0.0001) CD4+ T-cell proportions among IRs and INRs. Our study highlights that immune dysregulation associated with skewing of cTfh cells toward CXCR3+ CCR6− Th1-like phenotype may be the leading cause of inefficient CD4+ T-cell recovery in INRs and can serve as a hallmark of impaired CD4+ T-cell reconstitution. IMPORTANCE: The altered proportions of CD4+ T-cell subsets in immunological non-responders (INRs) indicate their involvement in poor CD4+ T-cell reconstitution. Reversing these alterations may help prevent the loss of CD4+ T cells. Particularly, blocking cTfh-cell polarization toward CXCR3+ CCR6− cTfh-cell subset may help restore CD4+ T-cell counts in INRs, thereby preventing increased risk of morbidity and mortality.


  • Neuropathogenesis of SARS-CoV-2 in human neuronal, microglial and glial cells

    by Narendra Kumar, Rashmi Santhoshkumar, Ragini Agrawal, Amit Singh, Vijayalakshmi Kalyan, Anita Desai, Vasanthapuram Ravi, Manjunatha M. Venkataswamy

    Neurological complications, both acute and chronic, are reported commonly in COVID-19 affected individuals. In this context, the understanding of pathogenesis of SARS-CoV-2 in specific cells of central nervous system (CNS) origin is relevant. The present study explores infection biology of a clinical isolate of SARS-CoV-2 in human cell lines of neural origin such as the glioblastoma (U87-MG), neuroblastoma (SHSY5Y) and microglia (C20). Despite showing clear evidence of infection by immunofluorescence with an anti-spike protein antibody, all the three neural cell lines were observed to be highly restrictive to the replication of the infecting virus. While the U87-MG glioblastoma cells demonstrated no cytopathic effects and a low viral titre with no signs of replication, the SHSY5Y neuroblastoma cells exhibited cytopathic effects with bleb formation but no evidence of viable virus. The C20 microglial cells showed neither signs of cytopathic effects nor viable virus. Ultrastructural studies demonstrated intracellular virions in infected neural cells. The presence of lipid droplets in infected SHSY5Y cells suggested an impact on host cell metabolism. The decrease in viral RNA levels over time in all the neural cell lines suggested restricted viral replication. In conclusion, this study highlights the limited susceptibility of neural cells to SARS-CoV-2 infection. This reduced permissibility of neural cell lines to SARS-CoV-2 may point to their inherent lower expression of receptors that support viral entry in addition to the intracellular factors that potently inhibit viral replication. The study findings prompt further investigation into the mechanisms of SARS-CoV-2 infection of neural cells.


  • Open Access

    Chikungunya virus infection in human microglial C20 cells induces mitochondria-mediated apoptosis

    by Narendra Kumar, Rashmi Santhoshkumar, Manjunatha M. Venkataswamy

    Introduction: Chikungunya virus (CHIKV) infection is associated with acute clinical manifestations and chronic joint inflammation. CHIKV has emerged as a significant causative agent of central nervous system (CNS) complications, including encephalitis and related sequelae. Microglial cells, crucial for immune responses and tissue repair in the CNS, play a vital role in the host response to viral infections, with their activation potentially leading to either protection or pathology. In this study, the infection biology of CHIKV in the C20 human microglial cell line was investigated.Methods: The permissiveness of C20 cells to CHIKV infection was assessed, and viral replication kinetics were compared to Vero E6 cells. Cytopathic effects of CHIKV infection on C20 cells were examined, along with ultrastructural changes using transmission electron microscopy. Additionally, apoptosis induction, mitochondrial membrane potential, and alterations in cell surface marker expression were evaluated by flow cytometry.Results: CHIKV infection demonstrated permissiveness in C20 cells, similar to Vero cells, resulting in robust viral replication and cytopathic effects. Ultrastructural analysis revealed viral replication, mature virion formation, and distinctive cytoplasmic and nuclear changes in infected C20 cells. CHIKV infection induced significant apoptosis in C20 cells, accompanied by mitochondrial membrane depolarization and altered expression of cell surface markers such as CD11c, CD14, and HLA-DR. Notably, decreased CD14 expression was observed in CHIKV-infected C20 cells.Discussion: The study findings suggest that CHIKV infection induces apoptosis in C20 microglial cells via the mitochondrial pathway, with significant alterations in cell surface marker expression, particularly CD14 that is linked with apoptosis induction. These observations provide valuable insights into the role of human microglial cells in the host response to CHIKV infection and contribute to the knowledge on the neuropathogenesis of this virus.


  • An ultrastructural and genomic study on the SARS-CoV-2 variant B.1.210 circulating during the first wave of COVID-19 pandemic in India

    by Narendra Kumar, Rashmi Santhoshkumar, Pramada Prasad, Anson K. George, Jayashree Aiyar, Saurabh Joshi, Gayathri Narayanappa, Anita S. Desai, Vasanthapuram Ravi, Manjunatha M. Venkataswamy


  • Infection of human microglial cell line CHME-3 to study neuropathogenesis of chikungunya virus

    by Syed Wasifa Qadri, Narendra Kumar, Rashmi Santhoshkumar, Anita Desai, Vasanthapuram Ravi, Manjunatha M. Venkataswamy

    Chikungunya virus (CHIKV) infection, generally characterised by fever, rash and debilitating polyarthralgia, and/or arthritis, also causes complications of the central nervous system, including encephalitis. However, the role of microglial cells in the neuropathogenesis of CHIKV is poorly understood. The current study characterised the progression of CHIKV infection in the human microglial cell line CHME-3. The susceptibility of these cells to CHIKV and the viral replication kinetics were assessed during the early and late phases of infection. The cell viability was determined using the cell viability assay. Ultrastructural changes in CHIKV infected CHME-3 cells were assessed using transmission electron microscopy. The results showed that CHME-3 cells are susceptible to CHIKV infection and support viral replication with no significant loss in cell viability until 72 h post infection. Ultrastructural studies revealed the formation of cytopathic vacuoles-I (CPV-I) in the early stages and CPV-II in later stages with several virions organized along the membrane of CPV-II. Profuse vacuolation was observed in the later stages of infection. Abnormal giant mitochondria with altered cristae were observed in infected cells with an electron-dense matrix. The study establishes CHME-3 cells as a potential model for investigating the role of human microglial cells in neuropathogenicity of CHIKV.


  • Open Access

    Epidemiology of SARS-CoV-2 infection in Karnataka State, South India: Transmission dynamics of symptomatic vs. asymptomatic infections

    by Narendra Kumar, Shafeeq K Shahul Hameed, Giridhara R Babu, Manjunatha M Venkataswamy, Prameela Dinesh, Prakash B G Kumar, Daisy A. John, Anita Desai, Vasanthapuram Ravi

    Background: In this report, we describe the epidemiology of SARS-CoV-2 infection, specifically examining how the symptomatic persons drove the transmission in the state of Karnataka, India, during the lockdown phase. Methods: The study included all the cases reported from March 8 to May 31, 2020 in the state. Any person with history of international or domestic travel from high burden states, those presenting with Influenza-like or Severe Acute Respiratory Illness and high-risk contacts of COVID19 cases, who were SARS-CoV-2 RT-PCR positive were included. Detailed analysis based on contact tracing data available from line-list of the state surveillance unit was performed using cluster analysis software package. Findings: Amongst the 3404 COVID-19 positive cases, 3096 (91%) were asymptomatic while 308 (9%) were symptomatic. Majority of the asymptomatic cases were in the age range of 16-50 years while symptomatic cases were between 31-65 years. Most of those affected were males. Cluster analysis of 822 cases indicated that the secondary attack rate, size of the cluster (dispersion) and occurrence of overt clinical illness is significantly higher when the index case in a cluster was symptomatic compared to an asymptomatic. Interpretation: Our findings indicate that both asymptomatic and symptomatic SARS-CoV-2 cases transmit the infection; however, the main driving force behind the spread of infection within the state was significantly higher from symptomatic cases. This has major implications for policies related to testing. Active search for symptomatic cases, subjecting them to testing and treatment should be prioritized for containing the spread of COVID-19. Funding: Intermediate Fellowship, Wellcome Trust-DBT India Alliance to Giridhara R Babu, Grant number: IA/CPHI/14/1/501499.


  • Open Access

    Genomic epidemiology reveals multiple introductions and spread of SARS-CoV-2 in the Indian state of Karnataka

    by Chitra Pattabiraman, Farhat Habib, Pk Harsha, Risha Rasheed, Vijayalakshmi Reddy, Prameela Dinesh, Tina Damodar, Kiran Hosallimath, Anson K George, Nakka Vijay Kiran Reddy, et al.

    An earlier version of this manuscript was removed owing to inclusion of confidential information relating to an individual


  • Immune aberrations in children with Autism Spectrum Disorder: a case-control study from a tertiary care neuropsychiatric hospital in India

    by Salah Basheer, Manjunatha M. Venkataswamy, Rita Christopher, Therese Van Amelsvoort, Shoba Srinath, Satish Chandra Girimaji, Vasanthapuram Ravi


  • Open Access

    Cellular immune response following pre-exposure and postexposure rabies vaccination by intradermal and intramuscular routes

    by Manjunatha Muniswamappa Venkataswamy, Shampur Narayan Madhusudana, Sampada Sudarshan Sanyal, Shaheen Taj, Ashwin Yajaman Belludi, Reeta Subramaniam Mani, Nandita Hazra

    Venkataswamy MM, et al. Clin Exp Vaccine Res. 2015 Jan;4(1):68-74. http://dx.doi.org/10.7774/cevr.2015.4.1.68